An­ti-ag­ing start­up Ele­vian en­lists In­sil­i­co on AI quest for 'y­oung blood'

Some of the ear­li­est con­nec­tions Alex Zha­voronkov has built for his AI shop at In­sil­i­co Med­i­cine in­volves mar­ry­ing an­ti-ag­ing and AI re­search, two of the buzzi­est ar­eas in drug de­vel­op­ment. He’s now dou­bling down on it with a new R&D part­ner­ship with “young blood” start­up Ele­vian.

The col­lab­o­ra­tion is aimed at de­vel­op­ing oral med­ica­tions tar­get­ing the GDF11, or growth dif­fer­en­ti­a­tion fac­tor 11, path­way and as­so­ci­at­ed tar­gets — a con­cept that Ele­vian has been work­ing on since in­cep­tion. Ele­vian is sup­ply­ing the bi­o­log­i­cal and struc­tur­al tar­get da­ta that In­sil­i­co will use to iden­ti­fy small mol­e­cules via its gen­er­a­tive ad­ver­sar­i­al net­works (GANs) and re­in­force­ment learn­ing (RL) AI tech­nolo­gies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.